Development of anti-HTLV-1 therapies towards active interventions for high-risk carriers
Project/Area Number |
15K08439
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Experimental pathology
|
Research Institution | National Institute of Infectious Diseases |
Principal Investigator |
OKUMA Kazu 国立感染症研究所, 血液・安全性研究部, 室長 (80315085)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | HTLV-1感染 / HTLV-1感染細胞 / 治療法開発 / 組換えタンパク質治療薬 / 組換えウイルス治療薬 / ヒト化マウス感染モデル / HTLV-1感染制御 / 組換え水疱性口内炎ウイルス / HTLV-1感染受容体 / HTLV-1エンベロープタンパク質 / ウイルス療法 / 疾患発症予防 / 感染細胞 / 標的化 / TSLC1 / CRTAM / 緑膿菌エクソトキシン / HTLV-1 / ATL発症予防 / プロウイルス量 / CCR4 / CCL17 / 緑膿菌エキソトキシン / ヒト化マウス |
Outline of Final Research Achievements |
In this study, to establish antiviral therapies against human T-cell leukemia virus type 1 (HTLV-1) infection for HTLV-1-infected individuals (carriers), we developed two candidate drugs that can eliminate HTLV-1 by targeting and killing HTLV-1-infected cells: "a recombinant protein", truncated Pseudomonas exotoxin fused to CCL17 (a CCR4 ligand) to target CCR4 frequently expressed on HTLV-1-infected cells, and "a recombinant vesicular stomatitis virus" lacking the G gene and instead encoding HTLV-1 receptor, neuropilin 1, to target HTLV-1 envelope protein specifically expressed on HTLV-1-infected cells. We tested whether these candidate drugs selectively eliminated such infected cells, leading to the control of HTLV-1 infection in vitro and in vivo. Our present findings strongly indicated the therapeutic potential of these candidate anti-HTLV-1 drugs.
|
Report
(4 results)
Research Products
(8 results)
-
-
-
[Journal Article] Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.2015
Author(s)
Okuma K, Hiyoshi M, Tateyama S, Takizawa K, Saito M, Kuramitsu M, Araki K, Morishita K, Okada S, Yamamoto N, Biragyn A, Yamaguchi K, Hamaguchi I.
-
Journal Title
Retrovirology
Volume: 12
Issue: 1
Pages: 1-14
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
-
-
-